These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 31852884)

  • 1. The impact of oncogenic RAS on redox balance and implications for cancer development.
    Lim JKM; Leprivier G
    Cell Death Dis; 2019 Dec; 10(12):955. PubMed ID: 31852884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance.
    Lim JKM; Delaidelli A; Minaker SW; Zhang HF; Colovic M; Yang H; Negri GL; von Karstedt S; Lockwood WW; Schaffer P; Leprivier G; Sorensen PH
    Proc Natl Acad Sci U S A; 2019 May; 116(19):9433-9442. PubMed ID: 31000598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating The Role Of Nitric Oxide Synthase In Oncogenic Ras-Driven Tumorigenesis.
    Counter C
    Redox Biol; 2015 Aug; 5():417. PubMed ID: 28162280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
    Huang L; Counter CM
    PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
    Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
    Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cysteine-based regulation of redox-sensitive Ras small GTPases.
    Messina S; De Simone G; Ascenzi P
    Redox Biol; 2019 Sep; 26():101282. PubMed ID: 31386964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAS-mediated oncogenic signaling pathways in human malignancies.
    Khan AQ; Kuttikrishnan S; Siveen KS; Prabhu KS; Shanmugakonar M; Al-Naemi HA; Haris M; Dermime S; Uddin S
    Semin Cancer Biol; 2019 Feb; 54():1-13. PubMed ID: 29524560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
    Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
    Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic Ras Isoforms Signaling Specificity at the Membrane.
    Nussinov R; Tsai CJ; Jang H
    Cancer Res; 2018 Feb; 78(3):593-602. PubMed ID: 29273632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the RAS-dependent chemoresistance: The Warburg connection.
    Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
    Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The renewed battle against RAS-mutant cancers.
    Zhang F; Cheong JK
    Cell Mol Life Sci; 2016 May; 73(9):1845-58. PubMed ID: 26892781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sec5 and Exo84 foster oncogenic ras-mediated tumorigenesis.
    Issaq SH; Lim KH; Counter CM
    Mol Cancer Res; 2010 Feb; 8(2):223-31. PubMed ID: 20145037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry.
    Young TW; Mei FC; Yang G; Thompson-Lanza JA; Liu J; Cheng X
    Cancer Res; 2004 Jul; 64(13):4577-84. PubMed ID: 15231669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1.
    Lucas L; Penalva V; Ramírez de Molina A; Del Peso L; Lacal JC
    Int J Oncol; 2002 Sep; 21(3):477-85. PubMed ID: 12168089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in
    Sheffels E; Sealover NE; Theard PL; Kortum RL
    Small GTPases; 2021 Jan; 12(1):67-78. PubMed ID: 31062644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Wild-Type RAS in Oncogenic RAS Transformation.
    Sheffels E; Kortum RL
    Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33924994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MTH1 expression is required for effective transformation by oncogenic HRAS.
    Giribaldi MG; Munoz A; Halvorsen K; Patel A; Rai P
    Oncotarget; 2015 May; 6(13):11519-29. PubMed ID: 25893378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic KRAS promotes malignant brain tumors in zebrafish.
    Ju B; Chen W; Orr BA; Spitsbergen JM; Jia S; Eden CJ; Henson HE; Taylor MR
    Mol Cancer; 2015 Feb; 14(1):18. PubMed ID: 25644510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Synthetic Lethal Interaction between Glutathione Synthesis and Mitochondrial Reactive Oxygen Species Provides a Tumor-Specific Vulnerability Dependent on STAT3.
    Garama DJ; Harris TJ; White CL; Rossello FJ; Abdul-Hay M; Gough DJ; Levy DE
    Mol Cell Biol; 2015 Nov; 35(21):3646-56. PubMed ID: 26283727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.